No PFAS in Cosmetics Act

Proposals impacting the pharmaceutical supply chain -- no bill number S.2100 - A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. H.R.3990/S. 2047 - To ban the use of intentionally added perfluoroalkyl or polyfluoroalkyl substances in cosmetics. H.R.5376 - Build Back Better Act H.R.3684 - Infrastructure Investment and Jobs Act

Client expense: $160,270 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE

Issues related to the safety of cosmetics, counterfeit products; FDA OTC Monograph Reform implementation; FDA sunscreen regulation; H.R. ___, Cosmetic Safety Enhancement Act; S. 936/H.R. 5502, Integrity, Notification, and Fairness in Online Retail Marketplaces (INFORM) for Consumers Act; S. 1843/H.R. 3429, Stopping Harmful Offers on Platforms by Screening Against Fakes in E-commerce (SHOP SAFE) Act; S. 2047/H.R. 3990, No PFAS in Cosmetics Act; S. 2100, Personal Care Products Safety Act; H.R. 2467, PFAS Action Act of 2021; H.R. 4800/S. 2546, Reef Safe Act; H.R. 5537, Toxic-free Beauty Act of 2021; H.R. 5538, Cosmetic Fragrance and Flavor Ingredient Right to Know Act of 2021; H.R. 5539, Cosmetic Supply Chain Transparency Act of 2021; H.R. 5540, Cosmetic Safety for Communities of Color and Professional Salon Workers Act of 2021; H.R. 5872, Natural Cosmetics Act; H.R. 2617, Consolidated Appropriations Act, 2023 - Modernization of Cosmetics Regulation Act (MoCRA) of 2022

Client expense: $360,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Issues related to the safety of cosmetics, counterfeit products; FDA OTC Monograph Reform implementation; FDA sunscreen regulation; H.R. ___, Cosmetic Safety Enhancement Act; S. 936/H.R. 5502, Integrity, Notification, and Fairness in Online Retail Marketplaces (INFORM) for Consumers Act; S. 1843/H.R. 3429, Stopping Harmful Offers on Platforms by Screening Against Fakes in E-commerce (SHOP SAFE) Act; S. 2047/H.R. 3990, No PFAS in Cosmetics Act; S. 2100, Personal Care Products Safety Act; H.R. 2467, PFAS Action Act of 2021; H.R. 4800/S. 2546, Reef Safe Act; H.R. 5537, Toxic-free Beauty Act of 2021; H.R. 5538, Cosmetic Fragrance and Flavor Ingredient Right to Know Act of 2021; H.R. 5539, Cosmetic Supply Chain Transparency Act of 2021; H.R. 5540, Cosmetic Safety for Communities of Color and Professional Salon Workers Act of 2021; H.R. 5872, Natural Cosmetics Act; H.R. 2617, Consolidated Appropriations Act, 2023 - Modernization of Cosmetics Regulation Act (MoCRA) of 2022

Client expense: $360,000 · Firm income: Not reported

H.R. 1015: Water Recycling Investment and Improvement Act; issues related to Wastewater Infrastructure Funding H.R. 1915: Water Quality Protection and Job Creation Act of 2021; all provisions of the bill H.R. 2467: PFAS Action Act; all provisions of the bill H.R. 3990: No PFAS in Cosmetics Act; all provisions of the bill H.R. 4602: Wastewater Infrastructure Pollution Prevention and Environmental Safety (WIPPES) Act; all provisions of the bill H.R. 4099: Large-Scale Water Recycling Project Investment Act; all provisions of the bill H.R. 6591: PIPES Act; Large Scale Water Recycling Program Implementation Act; all provisions of the bill S. 1459: Protecting Unique and Beautiful Landscapes by Investing in California (PUBLIC) Lands Act; all provisions of the bill S. 2047: No PFAS in Cosmetics Act; all provisions of the bill S. 2334: Large Scale Water Recycling Project and Drought Resiliency Investment Act; all provisions of the bill Public Law No: 117-58 (H.R. 3684): Infrastructure Investment and Jobs Act; Wastewater and Ocean Monitoring, Wastewater Epidemiology; issues related to PFAS and Title XVI Funding Discussions related to Buy America regarding Water Infrastructure Funding Programs Discussions related to Large Scale Water Recycling Program Implementation

Client expense: Not reported · Firm income: $10,000

H.R. 1015: Water Recycling Investment and Improvement Act; issues related to Wastewater Infrastructure Funding H.R. 1915: Water Quality Protection and Job Creation Act of 2021; all provisions of the bill H.R. 2467: PFAS Action Act; all provisions of the bill H.R. 3990: No PFAS in Cosmetics Act; all provisions of the bill H.R. 4602: Wastewater Infrastructure Pollution Prevention and Environmental Safety (WIPPES) Act; all provisions of the bill H.R. 4099: Large-Scale Water Recycling Project Investment Act; all provisions of the bill H.R. 6591: PIPES Act; all provisions of the bill S. 1459: Protecting Unique and Beautiful Landscapes by Investing in California (PUBLIC) Lands Act; all provisions of the bill S. 2047: No PFAS in Cosmetics Act; all provisions of the bill S. 2334: Large Scale Water Recycling Project and Drought Resiliency Investment Act; all provisions of the bill Discussions related to Buy America regarding Water Infrastructure Funding Programs Discussions related to Large Scale Water Recycling Program Implementation Public Law No: 117-58 (H.R. 3684): Infrastructure Investment and Jobs Act; Wastewater and Ocean Monitoring, Wastewater Epidemiology; issues related to PFAS and Title XVI Funding

Client expense: Not reported · Firm income: $10,000

- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation

S. 936/H.R. 5502, Integrity, Notification, and Fairness in Online Retail Marketplaces (INFORM) for Consumers Act; S. 1843/H.R. 3429, Stopping Harmful Offers on Platforms by Screening Against Fakes in E-commerce (SHOP SAFE) Act; S. 2047/H.R. 3990, No PFAS in Cosmetics Act;

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Support public health protections in implementation of the Lautenberg Chemical Safety Act of 2016 Support measures to protect public health and the environment from toxic chemical hazards, including: H.R.2467 - PFAS Action Act of 2021 S.1334 - PFAS Accountability Act of 2021 H.R.4463 - PFAS Safe Disposal Act H.R.3990 /S.2047 - No PFAS in Cosmetics Act S.1121/ H.R.2742 - PFAS Registry Act of 2021 S.3169 / H.R.6026 - Keep Food Containers Safe from PFAS Act of 2021 H.R.4241/ S.1973 - PFAS Filthy Fifty Act S.2406 - Protect Drinking Water from PFAS Act of 2021 S.2555 /H.R.4340 - PFAS Exposure Assessment and Documentation Act H.R.5987 - PFAS Definition Improvement Act S.4244/H.R.7810 -- Alan Reinstein Ban Asbestos Now Act of 2022

Client expense: Not reported · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the Consolidated Appropriations Act, 2023 (H.R.2617), FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R.2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the Consolidated Appropriations Act, 2023 (H.R.2617), FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R.2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the Consolidated Appropriations Act, 2023 (H.R.2617), FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R.2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the Consolidated Appropriations Act, 2023 (H.R.2617), FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R.2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the Consolidated Appropriations Act, 2023 (H.R.2617), FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R.2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Consolidated Appropriations Act, 2023 (H.R.2617), the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Consolidated Appropriations Act, 2023 (H.R.2617), the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Consolidated Appropriations Act, 2023 (H.R.2617), the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Consolidated Appropriations Act, 2023 (H.R.2617), the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

Proposals impacting the pharmaceutical supply chain -- no bill number S.2100 - A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. H.R.3990/S. 2047 - To ban the use of intentionally added perfluoroalkyl or polyfluoroalkyl substances in cosmetics. H.R.5376 - Build Back Better Act H.R.3684 - Infrastructure Investment and Jobs Act

Client expense: $178,500 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE

Issues related to regulation of cosmetics, including S.2100, the Personal Care Products Safety Act; and S.2047, A bill to ban the use of intentionally added polyfluoroalkyl substances in cosmetics, S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 6833, making continuing appropriations for fiscal year 2023; and H.R. 2617, Consolidated Appropriations Act. Issues related to counterfeit products, including S.936, the INFORM Consumers Act and S.1843, the SHOP Safe Act, and and H.R. 2617, Consolidated Appropriations Act. Issues related to animal testing, sunscreen, CBD, and the COVID-19 pandemic.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to regulation of cosmetics, including S.2100, the Personal Care Products Safety Act; and S.2047, A bill to ban the use of intentionally added polyfluoroalkyl substances in cosmetics, S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 6833, making continuing appropriations for fiscal year 2023; and H.R. 2617, Consolidated Appropriations Act. Issues related to animal testing, sunscreen, CBD, and the COVID-19 pandemic.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Support public health protections in implementation of the Lautenberg Chemical Safety Act of 2016 Support measures to protect public health and the environment from toxic chemical hazards, including: H.R.2467 - PFAS Action Act of 2021 S.1334 - PFAS Accountability Act of 2021 H.R.4463 - PFAS Safe Disposal Act H.R.3990 /S.2047 - No PFAS in Cosmetics Act S.1121/ H.R.2742 - PFAS Registry Act of 2021 S.3169 / H.R.6026 - Keep Food Containers Safe from PFAS Act of 2021 H.R.4241/ S.1973 - PFAS Filthy Fifty Act S.2406 - Protect Drinking Water from PFAS Act of 2021 S.2555 /H.R.4340 - PFAS Exposure Assessment and Documentation Act H.R.5987 - PFAS Definition Improvement Act S.4244/H.R.7810 -- Alan Reinstein Ban Asbestos Now Act of 2022

Client expense: $6,630 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE

Issues related to regulation of cosmetics, including S.2100, the Personal Care Products Safety Act; and S.2047, A bill to ban the use of intentionally added polyfluoroalkyl substances in cosmetics, S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R. 6833, making continuing appropriations for fiscal year 2023. Issues related to animal testing, sunscreen, CBD, and the COVID-19 pandemic.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to regulation of cosmetics, including S.2100, the Personal Care Products Safety Act; and S.2047, A bill to ban the use of intentionally added polyfluoroalkyl substances in cosmetics, S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R. 6833, making continuing appropriations for fiscal year 2023. Issues related to counterfeit products, including S.936, the INFORM Consumers Act and S.1843, the SHOP Safe Act. Issues related to animal testing, sunscreen, CBD, and the COVID-19 pandemic.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R. 2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R. 2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R. 2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R. 2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R. 2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

Issues related to the safety of cosmetics, counterfeit products; FDA OTC Monograph Reform implementation; FDA sunscreen regulation; H.R. ___, Cosmetic Safety Enhancement Act; S. 936/H.R. 5502, Integrity, Notification, and Fairness in Online Retail Marketplaces (INFORM) for Consumers Act; S. 1843/H.R. 3429, Stopping Harmful Offers on Platforms by Screening Against Fakes in E-commerce (SHOP SAFE) Act; S. 2047/H.R. 3990, No PFAS in Cosmetics Act; S. 2100, Personal Care Products Safety Act; H.R. 2476, PFAS Action Act of 2021; H.R. 4800/S. 2546, Reef Safe Act; H.R. 5537, Toxic-free Beauty Act of 2021; H.R. 5538, Cosmetic Fragrance and Flavor Ingredient Right to Know Act of 2021; H.R. 5539, Cosmetic Supply Chain Transparency Act of 2021; H.R. 5540, Cosmetic Safety for Communities of Color and Professional Salon Workers Act of 2021; H.R. 5872, Natural Cosmetics Act

Client expense: $360,000 · Firm income: Not reported

Proposals impacting the pharmaceutical supply chain -- no bill number S.2100 - A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. H.R.3990/S. 2047 - To ban the use of intentionally added perfluoroalkyl or polyfluoroalkyl substances in cosmetics. H.R.5376 - Build Back Better Act H.R.3684 - Infrastructure Investment and Jobs Act

Client expense: $142,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE

Support public health protections in implementation of the Lautenberg Chemical Safety Act of 2016 Support measures to protect public health and the environment from toxic chemical hazards, including: H.R.2467 - PFAS Action Act of 2021 S.1334 - PFAS Accountability Act of 2021 H.R.4463 - PFAS Safe Disposal Act H.R.3990 /S.2047 - No PFAS in Cosmetics Act S.1121/ H.R.2742 - PFAS Registry Act of 2021 S.3169 / H.R.6026 - Keep Food Containers Safe from PFAS Act of 2021 H.R.4241/ S.1973 - PFAS Filthy Fifty Act S.2406 - Protect Drinking Water from PFAS Act of 2021 S.2555 /H.R.4340 - PFAS Exposure Assessment and Documentation Act H.R.5987 - PFAS Definition Improvement Act S.4244/H.R.7810 -- Alan Reinstein Ban Asbestos Now Act of 2022

Client expense: $6,298 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE

- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation

Issues related to the safety of cosmetics, counterfeit products; FDA OTC Monograph Reform implementation; FDA sunscreen regulation; H.R. ___, Cosmetic Safety Enhancement Act; S. 936/H.R. 5502, Integrity, Notification, and Fairness in Online Retail Marketplaces (INFORM) for Consumers Act; S. 1843/H.R. 3429, Stopping Harmful Offers on Platforms by Screening Against Fakes in E-commerce (SHOP SAFE) Act; S. 2047/H.R. 3990, No PFAS in Cosmetics Act; S. 2100, Personal Care Products Safety Act; H.R. 2476, PFAS Action Act of 2021; H.R. 4800/S. 2546, Reef Safe Act; H.R. 5537, Toxic-free Beauty Act of 2021; H.R. 5538, Cosmetic Fragrance and Flavor Ingredient Right to Know Act of 2021; H.R. 5539, Cosmetic Supply Chain Transparency Act of 2021; H.R. 5540, Cosmetic Safety for Communities of Color and Professional Salon Workers Act of 2021; H.R. 5872, Natural Cosmetics Act

Client expense: $380,000 · Firm income: Not reported

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R. 2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $10,000

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R. 2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $10,000

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R. 2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $10,000

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R. 2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $10,000

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R. 2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $10,000

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000